{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.87","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment A over Treatment B","nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.74","statisticalMethod":"Stratified Cox proportional hazard model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.93","upperLimit":"19.71","value":"15.80"},{"groupId":"OG001","lowerLimit":"9.49","upperLimit":"12.71","value":"10.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants, Global Population","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)","title":"Overall Survival (OS)","type":"POST_HOC","unitOfMeasure":"Months"}